The SMS Pharmaceuticals share price had a sharp move today after a crucial regulatory update stirred fresh excitement in the market. The stock saw a strong rally as investors reacted to the approval of the company’s reformulated Ranitidine tablets, bringing back a medicine that has been missing from the US market for years.
For a company rooted in pharmaceutical manufacturing, this approval isn’t just a regulatory green signal — it’s a story of revival and regained confidence.
Market Performance: SMS Pharmaceuticals Shares Show Strong Momentum
The SMS Pharmaceuticals share price today opened at ₹279.10 on the BSE.
As trading progressed, the stock climbed sharply, hitting an intraday high of ₹319.90, while the day’s low stood at ₹279.05.
The nearly 17% surge came immediately after the USFDA cleared its reformulated Ranitidine tablets.
This move placed SMS Pharmaceuticals among the top trending stocks of the day, with traders closely tracking the sudden jump in both price and activity.
Main News: USFDA Approval Brings Ranitidine Tablets Back to US Market
The biggest development came from the US FDA’s decision to approve the company’s reformulated Ranitidine tablets in 150 mg and 300 mg strengths, manufactured by its partner VKT Pharma.
This drug has long been linked to treating gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related issues.
But due to NDMA impurity concerns, it had been absent from the US market for nearly five years.
The new approval arrived only after extensive safety checks and improved manufacturing processes designed to address earlier quality issues.
For many patients relying on acid-reducing medications, this represents renewed access to a widely used treatment option.
The update naturally lifted sentiment around SMS Pharmaceuticals, as the drug’s return plays a key part in the company’s US product portfolio.
Company Details: Strong Q2 Results Add to the Momentum
Alongside the regulatory update, the company recently reported a strong quarterly performance.
Here’s a clean breakdown of the financials for the quarter ending September 30, 2025:
- Net Profit: ₹25.14 crore, up 76.4% YoY (from ₹14.25 crore)
- Operating Revenue: ₹242.4 crore, up 23.2% YoY (from ₹196.7 crore)
- EBITDA: ₹48.34 crore, up 51.8% YoY (from ₹31.85 crore)
- EBITDA Margin: 19.94%, higher than 16.19% last year
These numbers reflect stronger demand and an improved product mix, giving the company a deeper footing in key segments.
Summary: SMS Pharmaceuticals Share Price Outlook & Key Updates
Today’s surge in the SMS Pharmaceuticals share price mirrors the importance of the USFDA approval for its reformulated Ranitidine tablets.
After years of safety-related absence, the drug’s return marks a milestone for the company and opens the door for renewed presence in an important global market.
With:
- A 17% jump driven by regulatory approval
- Strong Q2 performance with 76.4% YoY net profit growth
- Rising revenue, EBITDA, and margins
The stock stayed firmly in focus throughout the session.
The developments also keep SMS Pharmaceuticals, Ranitidine tablets, and USFDA approval updates among the key searched terms across the pharma news space.
Easy & quick
Leave A Comment?